Successful brands such as Rituxan, Herceptin and Erbitux are all expectedto grow by anywhere from 23% to 80% by 2013. Furthermore, there areseveral monoclonal antibodies, such as Amgen's Denosumab and Bristol-MyersSquibb's ipilumumab, in development poised to experience similar growthafter they launch.

The new report, "The Oncology Market Forecast to 2013," is a comprehensivestudy of more than 135 oncology drugs. The study includes detailedforecasts for each drug, including forecasts for individual drug classesand top oncology drug manufacturers. Download a complimentary brochurehere: http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp

"In this era where blockbuster drugs are few and far between, the cancermarket is one area that is poised for tremendous growth," said Eric Bolesh,research team leader at Cutting Edge Information. "The amount of researchdollars that the pharma industry is spending on oncology drug developmentis sure to deliver new market leaders in the next five years."

Monoclonal antibodies' (MAbs) efficacy and diminished side effects makethem an attractive choice for oncologists. In 2007, MAb sales leapt by $3billion over 2006 levels to almost $14 billion. This increase comes thanksto the three highest-selling MAbs -- Herceptin, Rituxan and Avastin, whichcombined for more than $12.4 billion in 2007 after 2006 sales of $9.7billion.

MAb sales will continue to grow by a steady $2 billion to $3 billion peryear. Herceptin, Rituxan, Avastin and Erbitux will maintain marketdominance with nearly $25 billion in sales by 2012, or 89% of the MAbmarket. In addition, six new MAbs are slotted for launch in the next twoyears.

The 420+ page study examines 17 monoclonal antibodies and more than 120other drugs, and provides the following market analysis:

--  Individual Drug Profiles - Drug profiles include information about    drugs' competitive, strategic and market growth positions.--  Oncology Indication Market Outlook - Detailed outlooks for the breast,    colorectal, lung and prostate cancer and leukemia markets.--  Company Profiles - Oncology breakdowns for companies that either have    established oncology franchises or exciting development pipelines for new    cancer compounds.